Medpace Holdings, Inc. (NASDAQ:MEDP) Forecasted to Post FY2024 Earnings of $11.07 Per Share

Medpace Holdings, Inc. (NASDAQ:MEDP) – Analysts at William Blair lifted their FY2024 earnings per share (EPS) estimates for shares of Medpace in a report issued on Tuesday, April 23rd. William Blair analyst M. Smock now anticipates that the company will earn $11.07 per share for the year, up from their previous estimate of $10.55. The consensus estimate for Medpace’s current full-year earnings is $11.13 per share. William Blair also issued estimates for Medpace’s Q1 2025 earnings at $3.33 EPS and FY2025 earnings at $12.87 EPS.

Several other equities analysts also recently commented on MEDP. UBS Group upgraded Medpace from a “neutral” rating to a “buy” rating and increased their target price for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft assumed coverage on Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 price target for the company. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and increased their price target for the company from $340.00 to $450.00 in a research note on Tuesday. Finally, Guggenheim increased their price target on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $443.00.

Medpace Stock Down 2.0 %

Shares of MEDP stock opened at $389.77 on Thursday. The company has a market cap of $12.08 billion, a P/E ratio of 39.73, a P/E/G ratio of 2.04 and a beta of 1.38. Medpace has a twelve month low of $189.30 and a twelve month high of $421.00. The business has a fifty day simple moving average of $397.75 and a 200 day simple moving average of $324.12.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The business had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. During the same period in the prior year, the company earned $2.27 EPS. Medpace’s revenue for the quarter was up 17.7% on a year-over-year basis.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Wellington Management Group LLP lifted its holdings in Medpace by 312.6% during the third quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock worth $102,013,000 after acquiring an additional 319,210 shares during the period. TD Asset Management Inc raised its stake in shares of Medpace by 195.2% in the fourth quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock valued at $143,162,000 after buying an additional 308,816 shares during the period. Invesco Ltd. raised its stake in shares of Medpace by 67.6% in the third quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock valued at $148,159,000 after buying an additional 246,775 shares during the period. Norges Bank bought a new stake in shares of Medpace in the fourth quarter valued at $59,163,000. Finally, Epoch Investment Partners Inc. raised its stake in shares of Medpace by 82.3% in the fourth quarter. Epoch Investment Partners Inc. now owns 352,463 shares of the company’s stock valued at $108,040,000 after buying an additional 159,144 shares during the period. Institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling

In other Medpace news, VP Susan E. Burwig sold 102 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the sale, the vice president now owns 15,181 shares of the company’s stock, valued at $6,117,943. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, VP Susan E. Burwig sold 102 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the transaction, the vice president now owns 15,181 shares in the company, valued at $6,117,943. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the completion of the transaction, the insider now owns 5,525,959 shares in the company, valued at approximately $2,135,175,298.01. The disclosure for this sale can be found here. Insiders sold 189,340 shares of company stock valued at $76,651,647 over the last 90 days. Company insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.